Quest Diagnostics Inc Stock Price, News & Analysis

Quest Diagnostics (NYSE: DGX) outlined its strategic vision at its 2025 Investor Day, projecting 4-5% compound annual revenue growth and 7-9% adjusted EPS growth beyond 2025. The company's growth strategy focuses on expanding market access in physician and hospital channels, achieving double-digit growth in advanced diagnostics across five key clinical areas, and leveraging strategic partnerships.

Key initiatives include driving growth through diagnostic innovation, expanding hospital collaborative lab solutions, growing consumer-initiated testing via questhealth.com, and focusing on advanced diagnostics in oncology, cardiometabolic health, women's health, brain health, and autoimmune disorders. The company aims to achieve 3% annual productivity savings through its Invigorate initiative and modernize IT systems through Project Nova.

For Q1 2025, Quest expects weather-related impacts to create a $25 million revenue headwind and approximately $0.10 EPS impact.

Quest Diagnostics (NYSE: DGX) has announced a strategic collaboration with Google Cloud to enhance its data management and customer experience using generative AI technology. The partnership, announced on March 18, 2025, will utilize Google's Agentspace platform to connect employees and customers with enterprise-wide knowledge and automate complex tasks.

Quest will implement Google Cloud's data analytics and AI capabilities across various operations, including R&D, customer experience, and operations, with robust data privacy safeguards. The collaboration aims to help patients better understand their laboratory data and assist physicians in providing more personalized care.

With Quest processing over 200 million test requisitions and managing more than 80 billion datapoints in 2024, the partnership will leverage Google Cloud's HIPAA-compliant infrastructure and secure data storage. This initiative builds upon Quest's existing AI and automation implementations in areas such as microbiology, cytology testing, specimen processing, and customer service.

Fresenius Medical Care (XETRA: FME; NYSE: FMS), a global leader in renal disease care, announced the divestment of select assets of its wholly owned Spectra Laboratories to Quest Diagnostics (NYSE: DGX). Under the agreement, Quest will acquire laboratory assets focused on renal-specific testing in the U.S. Additionally, Quest will provide comprehensive dialysis-related lab and water testing services to Fresenius Medical Care's clinics in the U.S.

This acquisition will allow Quest to enhance its portfolio with dialysis-related water testing capabilities. The deal is expected to bring operational efficiencies to Fresenius Medical Care and leverage Quest's national scale, reducing transportation times and speeding up results reporting. Financial terms were not disclosed, and the acquisition is expected to close in the second half of 2025, with service transitions completing by early 2026.

Fresenius Medical Care is in the second year of a three-year strategic turnaround plan, focusing on optimizing its portfolio by divesting non-core and dilutive assets. Chronic kidney disease affects approximately 35.5 million people in the U.S., with over 800,000 receiving dialysis. This transaction aligns with Fresenius Medical Care's strategy to concentrate on its core business of providing dialysis care.

Quest Diagnostics (NYSE: DGX) has announced plans to host an Investor Day event on March 19, 2025 at the New York Stock Exchange. The event will feature presentations from key executives including Chairman, CEO and President Jim Davis, and Executive Vice President and CFO Sam Samad.

The leadership team will provide institutional investors and financial analysts with insights into several key areas including:

• Updated perspectives on the U.S. laboratory market
• Company's business strategy
• Capital deployment priorities
• Long-term outlook

The event requires advance registration and will be accessible via live webcast on Quest Diagnostics' Investor Relations website. An archived version of the webcast will be made available following the event's conclusion.

GRAIL (NASDAQ: GRAL) and Quest Diagnostics (NYSE: DGX) announced the integration of GRAIL's Galleri® multi-cancer early detection (MCED) test into Quest's test ordering system. This collaboration enables providers to order the Galleri test directly through Quest's Quanum laboratory portal and over 900 electronic health record systems.

The integration makes the test accessible at Quest's 7,400 patient access points nationwide, streamlining the ordering process for over 500,000 healthcare providers. The Galleri test, which detects cancer DNA fragments in blood before symptoms appear, is prescription-only and recommended for adults with elevated cancer risk, particularly those 50 or older.

This development builds upon their existing collaboration since 2021, aiming to improve cancer screening accessibility. The test can detect multiple deadly cancers, including those without current recommended screening tests, which account for nearly 70% of cancer deaths.

Quest Diagnostics (NYSE: DGX) has been named to Fortune magazine's 2025 World's Most Admired Companies™ list for the 11th consecutive year. The company ranked third in the 'Health Care: Pharmacy and Other Services' category, achieving top positions in seven of nine evaluation criteria.

The selection process, conducted in collaboration with Korn Ferry, involved surveying thousands of executives, directors, and analysts who rated companies based on nine key attributes including quality of products and services, innovation, and social responsibility. Quest secured top 1 or 2 positions in areas such as quality of management, long-term investment, product and service quality, social responsibility, and people management.

With over 55,000 employees, Quest Diagnostics continues its mission of creating a healthier world under the leadership of Chairman, CEO and President Jim Davis. Companies must rank in the top half of their industry survey to be included in this prestigious list, which analyzed 650 companies in total.

Quest Diagnostics (DGX) reported strong Q4 2024 financial results with revenues of $2.62 billion, up 14.5% year-over-year, and full-year revenues of $9.87 billion, up 6.7%. Q4 reported diluted EPS reached $1.95, increasing 14.7%, while adjusted diluted EPS was $2.23, up 3.7%.

The company completed eight acquisitions in 2024, including LifeLabs in Canada, expanded its health plan access to over 90% of in-network lives nationwide, and grew its Advanced Diagnostics portfolio. For 2025, Quest expects revenues between $10.70-10.85 billion and adjusted diluted EPS of $9.55-9.80.

The Board authorized a 6.7% increase in quarterly dividend to $0.80 per share, marking continuous dividend growth since 2011.

Quest Diagnostics (NYSE: DGX) has completed its previously announced acquisition of select assets from University Hospitals, a leading nonprofit health system and academic medical center. The acquisition expands Quest's presence in Ohio, providing broader access to its diagnostic testing services, patient access sites, and health plan coverage network.

Testing for University Hospitals' providers and patients using Quest's services will be performed at Quest's laboratories in Twinsburg, Ohio and Pittsburgh, Pennsylvania. University Hospitals will maintain operation of its hospital-based labs for inpatient and select outpatient testing. Financial terms of the acquisition were not disclosed.

Quest Diagnostics (NYSE: DGX) has appointed Adrienne L. Brott as senior vice president and chief quality and regulatory affairs officer, effective December 2024. Reporting to CEO Jim Davis, Brott will lead the company's quality and regulatory strategy, focusing on enhancing quality adherence and compliance with global regulations for laboratory diagnostic services.

Brott joins Quest with extensive experience in healthcare quality and regulatory affairs, previously serving as senior vice president of quality and regulatory at Getinge's acute care therapies division. Her prior roles include leadership positions at Becton Dickinson, where she managed quality across 28 manufacturing sites and led a program to harmonize 120 quality management systems. She also held positions at Johnson & Johnson and Abbott Laboratories.

The new executive is co-chair of the Advancing Quality Excellence Collaborative Community Steering Committee of the Medical Device Innovation Consortium, collaborating with stakeholders including the FDA to improve medical device quality and patient safety.